Journal Article

Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation

Giuffrida, Raffaella, Addeo, Raffaele, Tufano, Rossella, Caraglia, Michele, Nuzzo, Pier Vitale, Scrima, Marianna, Grisolia, Piera, Ceccarelli, Michele, Orditura, Michele, Iannarone, Clara, Graziano, Cinzia, Forte, Stefano, Carlino, Francesca, Ceccarelli, Anna, Cossu, Alessia Maria, De Falco, Antonio, Caraglia, Francesco

2024

Overview

Background Recent studies have highlighted the importance of the cell-free DNA (cfDNA) methylation profile in detecting breast cancer (BC) and its different subtypes. We investigated whether plasma cfDNA methylation, using cell-free Methylated DNA Immunoprecipitation and High-Throughput Sequencing (cfMeDIP-seq), may be informative in characterizing breast cancer in patients with BRCA1/2 germline mutations for early cancer detection and response to therapy. Methods We enrolled 23 BC patients with germline mutation of BRCA1 and BRCA2 genes, 19 healthy controls without BRCA1/2 mutation, and two healthy individuals who carried BRCA1/2 mutations. Blood samples were collected for all study subjects at the diagnosis, and plasma was isolated by centrifugation. Cell-free DNA was extracted from 1 mL of plasma, and cfMeDIP-seq was performed for each sample. Shallow whole genome sequencing was performed on the immuno-precipitated samples. Then, the differentially methylated 300-bp regions (DMRs) between 25 BRCA germline mutation carriers and 19 non-carriers were identified. DMRs were compared with tumor-specific regions from public datasets to perform an unbiased analysis. Finally, two statistical classifiers were trained based on the GLMnet and random forest model to evaluate if the identified DMRs could discriminate BRCA-positive from healthy samples. Results We identified 7,095 hypermethylated and 212 hypomethylated regions in 25 BRCA germline mutation carriers compared to 19 controls. These regions discriminate tumors from healthy samples with high accuracy and sensitivity. We show that the circulating tumor DNA of BRCA1/2 mutant breast cancers is characterized by the hypomethylation of genes involved in DNA repair and cell cycle. We uncovered the TFs associated with these DRMs and identified that proteins of the Erythroblast Transformation Specific (ETS) family are particularly active in the hypermethylated regions. Finally, we assessed that these regions could discriminate between BRCA positives from healthy samples with an AUC of 0.95, a sensitivity of 88%, and a specificity of 94.74%. Conclusions Our study emphasizes the importance of tumor cell-derived DNA methylation in BC, reporting a different methylation profile between patients carrying mutations in BRCA1, BRCA2, and wild-type controls. Our minimally invasive approach could allow early cancer diagnosis, assessment of minimal residual disease, and monitoring of response to therapy.

• Publisher: BioMed Central,BMC
• Subject: Adult / Biomedical and Life Sciences / Biomedicine / BRCA1 / BRCA1 Protein - genetics / BRCA2 / BRCA2 Protein - genetics / Breast cancer / Breast Neoplasms - blood / Breast Neoplasms - diagnosis / Breast Neoplasms - genetics / Case-Control Studies / Cell-free DNA / Cell-Free Nucleic Acids - blood / Cell-Free Nucleic Acids - genetics / cfMeDIP-seq / DMRs / DNA Methylation - genetics / Female / Germ-Line Mutation / High-Throughput Nucleotide Sequencing / Humans / Medical bioinformatics / Medicine/Public Health / Middle Aged / Mutation - genetics / ROC Curve